Cor Vasa 2006, 48(5):202-206

CHARISMA. The Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance trial

Jaromír Hradec¹, Jindřich Špinar²

¹ II. interní klinika, Všeobecná fakultní nemocnice a 1. lékařská fakulta Univerzity Karlovy, Praha

² Interní-kardiologická klinika, Fakultní nemocnice Brno a Lékařská fakulta Masarykovy univerzity, Brno, Česká republika

In the CHARISMA trial, the effect of 75 mg clopidogrel added to acetylsalicylic acid was evaluated in 15,603 patients with documented cardiovascular disease of atherosclerotic origin or at high risk of cardiovascular disease. The rates of the primary combined end point of efficacy-myocardial infarction, stroke or cardiovascular death-were 6.8% in patients treated with clopidogrel and 7.3% in patients on placebo (relative risk = 0.93; p = 0.22). While addition of clopidogrel to acetylsalicylic acid was not effective in patients in primary prevention (relative risk = 1.20; p = 0.20), the rate of the primary efficacy end point decreased significantly from 7.9% to 6.9% (relative risk = 0.88; p = 0.046) in secondary prevention.

Keywords: Clopidogrel; Dual antiplatelet therapy; Primary prevention; Secondary prevention

Published: May 1, 2006  Show citation